Participating Companies

De­vel­op­ing a po­ten­tial­ly best-in-class oral im­munother­a­py that ad­dress­es a broad range of food al­ler­gies. AD­P101, which is in a Ph 1/2 study and an OLE study, is de­signed to de­sen­si­tize pa­tients al­ler­g­ic to one or to mul­ti­ple foods si­mul­ta­ne­ous­ly to miti­gate the risk of se­vere, life-threat­en­ing al­ler­g­ic re­ac­tions. The Com­pany was co-found­ed by Dr. Kari Nadeau, a renowned food al­ler­gist, and former 23andMe ex­ec, Ash­ley Dom­bkows­ki who serves is CEO. Da­ta from Ph 1/2 study ex­pect­ed 1Q23. [more in­for­ma­tion]
Amphista Therapeutics
Am­phis­ta Ther­a­peu­tics has dis­cov­ered nov­el pro­pri­e­tary mech­anisms for Tar­get­ed Pro­tein Degra­da­tion (TPD), which can over­come the lim­i­ta­tions of other ap­proach­es. Our world-lead­ing team com­bines TPD pi­oneers, drug dis­cov­ery ex­perts and ex­pe­ri­enced biotech en­trepreneurs. • Iden­ti­fied nov­el de­grad­ing mech­anisms in­de­pen­dent of typ­i­cal E3 li­g­as­es [more in­for­ma­tion]
Arbor Biotechnologies
With the most ex­ten­sive li­brary of CRIS­PR nu­cleas­es in the in­dus­try, a deep bench of world-class foun­ders, sci­en­tif­ic ad­vi­sors, and a lead­er­ship team with a proven track re­cord of de­vel­op­ing nov­el plat­forms and ther­a­peu­tics, Ar­bor is well-po­si­tioned to de­vel­op cu­ra­tive ge­net­ic medicines for all pa­tients with ge­net­ic dis­eas­es. Ar­bor’s pipe­line is pow­ered by its pro­pri­e­tary biodis­cov­ery en­gine, which blends com­pu­ta­tio­n­al search and sci­en­tif­ic ex­per­tise to dis­cov­er, screen, and en­gi­neer pro­teins at un­prece­dent­ed scale and speed. Ar­bor has raised more than $300 mil­lion to date and top in­ves­tors in­clude ARCH Ven­ture Part­n­ers, Te­masek, Al­ly Bridge Group, and TCG Crossover. [more in­for­ma­tion]
They are build­ing a whol­ly-owned pipe­line of small-molecule drug can­di­dates, with three pro­grams in lead-op­ti­miza­tion and over 30 pro­grams in dis­cov­ery. The com­pany has raised over $174 mil­lion from lead­ing ven­ture cap­i­tal firms to ad­vance its mis­sion to make bet­ter medicines, faster. [more in­for­ma­tion]
The com­pany's gene cir­cuit­ry plat­form solves the cir­cuit­ry code, unique to each hu­man gene, fa­cil­i­tat­ing the rapid dis­cov­ery of new treat­ments. Its 4D maps iden­ti­fy de-risked drug­gable tar­gets, pro­duce ac­tion­able in­sights and im­prove ther­a­peu­tic pre­dicta­bil­i­ty. They are de­vel­op­ing a pipe­line of RNA Ac­tu­a­tor ther­a­peu­tic can­di­dates with the po­ten­tial to open up vast new hori­zons for pa­tients, and ex­plor­ing RNA Ac­tu­a­tors in mul­ti­ple in­di­ca­tions with ge­net­i­cal­ly vali­dat­ed tar­gets, ini­tial­ly fo­cus­ing on dis­eas­es of the liv­er and cen­tral ner­vous sys­tem. [more in­for­ma­tion]
Carisma Therapeutics Inc.
is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a dif­fer­en­ti­at­ed and pro­pri­e­tary cell ther­a­py plat­form fo­cused on en­gi­neered macrophages, cells that play a cru­cial role in both the in­nate and adap­tive im­mune re­sponse. The first ap­pli­ca­tions of the plat­form, de­vel­oped in col­lab­o­ra­tion with the Uni­ver­si­ty of Penn­syl­va­nia, are au­tol­o­gous chimer­ic anti­gen re­cep­tor (CAR)-macrophages for the treat­ment of solid tu­mors. CARIS­MA Ther­a­peu­tics is head­quar­tered in Philadel­phia, PA. [more in­for­ma­tion]
Catamaran Bio
Our pro­pri­e­tary ca­pa­bil­i­ties en­able us to har­ness the na­t­u­ral can­cer-fight­ing prop­er­ties of NK cells and en­hance and tailor their ef­fec­tive­ness with the pow­er of syn­thet­ic bi­ol­o­gy and in­no­va­tive non-vi­ral cell en­gi­neer­ing. We are us­ing our TAIL­WIND™ plat­form, an in­te­grat­ed suite of tech­nolo­gies, to spe­cif­i­cal­ly ad­dress the end-to-end meth­ods of en­gi­neer­ing, pro­cess­ing and man­u­fac­tur­ing NK cells and rapid­ly ad­vance our pipe­line of CAR-NK cell ther­a­py pro­grams. Our team com­bines ex­pe­ri­enced bio­phar­ma­ceu­ti­cal lead­er­ship with found­ing sci­en­tists who are pi­oneers in NK cell bi­ol­o­gy, en­gi­neer­ing, man­u­fac­tur­ing, and clin­i­cal ap­pli­ca­tion. [more in­for­ma­tion]
Celsius Therapeutics
Cel­sius Ther­a­peu­tics is a biotech­nol­o­gy com­pany that de­vel­ops pre­ci­sion medicines for can­cer and au­toim­mune dis­ease pa­tients. [more in­for­ma­tion]
Chameleon Biosciences
The com­pany's tech­nolo­gies in­clude ef­fec­tor vec­tors and exo-AAV which are not con­s­trained by the same im­mune sys­tem lim­i­ta­tions that pre­vent more wide­spread use of cur­rent AAV gene ther­a­pies, en­abling pa­tients to treat rare dis­eas­es with ge­net­ic medicines ad­min­is­tered as many times as need­ed. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia, astig­ma­tism, my­opia, my­opia pro­gres­sion) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Om­ni­fo­cal con­tact lens pres­by­opia 510k sub­mis­sion and my­opia pro­gres­sion clin­i­cal da­ta in 2H2022. Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
Cytoimmune Therapeutics
We aim to ac­quire rights to th­ese tech­nolo­gies by li­cens­ing or other­wise ac­quir­ing an own­er­ship in­ter­est in the tech­nolo­gies, fund­ing their re­search and de­vel­op­ment and even­tu­al­ly ei­ther out-li­cens­ing or bring­ing the tech­nolo­gies to mar­ket. Cur­rent­ly we are de­vel­op­ing our pro­pri­e­tary Chimer­ic Anti­gen Re­cep­tor (CAR) en­gi­neered NK cells (CAR-NK) tech­nol­o­gy, which we li­censed from the lab­o­ra­to­ries of Drs. Michael Caligi­uri and Jian­hua Yu at the Ci­ty of Hope Na­tio­n­al Med­i­cal Cen­ter (COH). [more in­for­ma­tion]
DTx Pharma
The com­pany's tech­nol­o­gy en­ables ef­fi­cient de­liv­ery of nu­cle­ic acid drugs to tis­sues through­out the body, en­abling health­care providers to de­liv­er oli­gos in vi­vo at ther­a­peu­ti­cal­ly rel­e­vant dos­es that work in many cell types in­clud­ing neu­rons, en­dothe­lial and T cells. Their pipe­line con­sists of nov­el ther­a­peu­tic can­di­dates to help pa­tients with neu­ro­mus­cu­lar, mus­cle, and CNS dis­eas­es. DTx has raised more than $100M in com­bined in­vest­ment from health­care in­ves­tors in­clud­ing RA Cap­i­tal and Ac­cess Biotech­nol­o­gy, phar­ma­ceu­ti­cal com­pa­nies such as Eli Lil­ly, the Na­tio­n­al In­sti­tute of Health (NIH), and re­search foun­da­tions such as the CMT Re­search Foun­da­tion (CMTRF). [more in­for­ma­tion]
Rec­og­niz­ing that the Phar­ma in­dus­try is on­ly be­gin­n­ing to un­der­s­tand how to po­ten­tial­ly op­ti­mize the ther­a­peu­tic ben­e­fits of T cell ther­a­pies (CART & TCRT) and with a great deal still to learn, En­terome is tak­ing a de­lib­er­ate­ly new and dif­fer­ent ap­proach with its tech­nol­o­gy plat­form en­abling each pa­tient to ben­e­fit from a spe­cif­ic and ma­jor ex­pan­sion of the best part of its own T cell reper­toire (Ef­fec­tor Me­m­o­ry T cells), in a high­ly so­phis­ti­cat­ed and un­prece­dent­ed way. Our On­coMim­icTM tech­nol­o­gy is en­abling the over­com­ing of im­mune tol­er­ance against can­cer cells with broad ap­pli­ca­bil­i­ty in the high un­met need solid tu­mor space via an off-the-shelf, easy to man­u­fac­ture tech­nol­o­gy. Our lead as­set EO2401 is cur­rent­ly in phase 2 in re­cur­rent Glioblas­to­ma (rGBM) and piv­o­tal trial in Adre­nal car­ci­no­ma (ACC). [more in­for­ma­tion]
Evox Therapeutics
Evox Ther­a­peu­tics is a pri­vate­ly held, Ox­ford-based biotech­nol­o­gy com­pany fo­cused on har­ness­ing and en­gi­neer­ing the na­t­u­ral de­liv­ery ca­pa­bil­i­ties of ex­tra­cel­lu­lar vesi­cles, known as ex­o­somes, to de­vel­op an en­tire­ly new class of ther­a­peu­tics. Backed by lead­ing life sci­ences ven­ture cap­i­tal groups and sup­port­ed by a com­pre­hen­sive in­tel­lec­tu­al prop­er­ty port­fo­lio, Evox’s mis­sion is to pos­i­tive­ly im­pact hu­man health by cre­at­ing nov­el ex­o­some-based ther­a­peu­tics for the treat­ment of vari­ous se­vere dis­eas­es with limit­ed op­tions for pa­tients and their fam­i­lies. Evox has cre­at­ed sub­s­tan­tial pro­pri­e­tary tech­nol­o­gy to mod­i­fy ex­o­somes us­ing vari­ous molec­u­lar en­gi­neer­ing, drug load­ing, and tar­get­ing strate­gies to fa­cil­i­tate tar­get­ed drug de­liv­ery to or­gans of in­ter­est, in­clud­ing the brain and the cen­tral ner­vous sys­tem. [more in­for­ma­tion]
Hangzhou Chance Pharmaceuticals
Chance fo­cus­es on in­ha­la­tion prod­ucts with pro­pri­e­tary tech­nolo­gies. [more in­for­ma­tion]
HotSpot Therapeutics
De­vel­op­er of a sys­te­m­at­ic way to cre­ate medicines based on reg­u­la­to­ry hotspots, or pres­sure points used by na­ture to con­trol pro­teins. The com­pany helps to iden­ti­fy hotspots and lo­cate path­way treat­ments for can­cer, metabolic and rare dis­eas­es. Its plat­form lev­er­ages a database of hotspot struc­tures, har­ness­ing the pow­er of da­ta sci­ence in its mul­tidis­ci­pli­nary ap­proach to drug dis­cov­ery. [more in­for­ma­tion]
Impact Therapeutics Inc
The JV is cur­rent­ly con­duct­ing a Phase II piv­o­tal study and a Phase III study of Se­na­parib in ovarian can­cer third-line treat­ment and first-line main­te­nance treat­ment in Chi­na. Out­side Chi­na, IM­PACT alone is con­duct­ing a Phase I/II study of Se­na­parib and te­mo­zolo­mide com­bi­na­tion ther­a­py in solid tu­mors and small cell lung can­cer treat­ment, as well as a Phase II study of Se­na­parib monother­a­py in pros­tate can­cer main­te­nance treat­ment. [more in­for­ma­tion]
Im­vax’s im­munother­a­py plat­form is a mul­ti-step pro­cess de­signed to de­liv­er per­so­n­al­ized, whole tu­mor-de­rived im­munother­a­pies. [more in­for­ma­tion]
In­vetx is build­ing the world’s pre­mi­er biotech­nol­o­gy plat­form for pro­tein-based ther­a­peu­tics in an­i­mal health to trans­form stan­dards of care in ve­t­eri­nary medicine. The In­vetx team of high­ly ex­pe­ri­enced R&D lead­ers from both hu­man biotech and an­i­mal health is sup­port­ed by best-in-class biotech­nol­o­gy part­n­ers and an ex­ten­sive net­work of in­dus­try ex­perts, ve­t­eri­nary sci­en­tists and clini­cians. In­vetx is a pri­vate com­pany head­quar­tered in Bos­ton, Mas­sachusetts. [more in­for­ma­tion]
Lassen Therapeutics
IL-11, a mem­ber of the IL-6 fam­i­ly of cy­tokines, is a cen­tral me­di­a­tor of fi­bro­sis and block­ing its ac­tiv­i­ty has the po­ten­tial to be more ef­fec­tive than tar­get­ing other fac­tors such as TGF-&be­ta; and CT­GF. IL-11 is al­so a piv­o­tal ef­fec­tor of tu­mor mi­croen­vi­ron­ment or­gani­za­tion and tu­mor growth, play­ing a key role as a me­di­a­tor be­tween can­cer and stro­mal cells. [more in­for­ma­tion]
LiPac Oncology
The com­pany is ad­vanc­ing mul­ti­ple or­phan in­di­ca­tions based on the estab­lished Li­Pax for­mu­la­tion that in­clude Urothe­lial Up­per Tract Urothe­lial Car­ci­no­ma, Stage II/III Ovarian Can­cer, In­traperi­toneal Car­ci­no­ma and Me­sothe­lio­ma/Ma­lig­nant Pleu­ral Ef­fu­sion. [more in­for­ma­tion]
MiNA Therapeutics
Lead­er in RNA ac­ti­va­tion (RNAa). Tech­nol­o­gy ca­pa­ble of drug­ging any pro­tein tar­get to in­crease na­t­u­ral pro­tein pro­duc­tion in pa­tients own cells. Im­muno-on­col­o­gy and rare dis­ease pipe­line with 10 clin­i­cal as­sets ex­pect­ed by 2025 and first FDA ap­pro­val in 2024. Key pro­grams in­clude MTL-CEP­BA (on­go­ing ran­domized Ph2 in 2L HCC, Ph1/1b in ad­vanced solid tu­mors re­sis­tant to an­ti-PD1), MTL-ST­ING, mono­gene­ic rare dis­ease pro­grams. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Minerva Biotechnologies
A clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing can­cer im­munother­a­pies and drugs to tar­get 75% of solid tu­mors and to pre­vent can­cer me­tas­ta­sis. Min­er­va has a pipe­line that in­cludes next-gen CAR Ts and other mo­dal­i­ties. The Com­pany has an on­go­ing Phase I/II study of huM­NC2-CAR44, an au­tol­o­gous CAR T ther­a­py, tar­get­ing the tu­mor-as­so­ci­at­ed form of MUC1 (MUC1*) which is a growth fac­tor re­cep­tor that drives growth of an es­ti­mat­ed 93% of breast can­cers. [more in­for­ma­tion]
MISSION Therapeutics
Mis­sion Ther­a­peu­tics is de­vel­op­ing a rich pipe­line of first-in-class small molecule DUB in­hibi­tors for a num­ber of sig­ni­f­i­cant clin­i­cal in­di­ca­tions. [more in­for­ma­tion]
NKGen Biotech
Lev­er­ag­ing our pro­pri­e­tary cell ex­pan­sion, su­per-ac­ti­va­tion tech­nol­o­gy and cutt­ing-edge cell man­u­fac­tur­ing ex­per­tise, we have the abil­i­ty to sig­ni­f­i­cant­ly ex­pand na­t­u­ral killer cells up to 190B fold while sub­s­tan­tial­ly in­creas­ing cy­to­toxic­i­ty across our pe­ripher­al blood-de­rived prod­ucts. NK­Gen Biotech’s lead prod­uct can­di­date, SNK01, is cur­rent­ly in Phase 1 and Phase 1/2a clin­i­cal trials for the treat­ment of ad­vanced re­frac­to­ry solid tu­mors both as a monother­a­py and in com­bi­na­tion with other agents in­clud­ing check­point in­hibi­tors and cell en­gagers. [more in­for­ma­tion]
NodThera Limited
Op­er­a­tor of a clin­i­cal-stage biotech­nol­o­gy com­pany in­tend­ed to de­vel­op medicines to treat dis­eas­es driv­en by chron­ic in­flam­ma­tion. The com­pany is fo­cused on de­vel­op­ing a new class of po­tent and se­lec­tive NL­R­P3 in­flam­ma­some in­hibi­tors, pro­vid­ing med­i­cal prac­ti­tion­ers with tools to help pa­tients with vari­ous chron­ic dis­eas­es. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Phase 2b ICO­NA NASH trial icos­abu­tate showed sig­ni­f­i­cant de­creas­es in NASH and fi­brot­ic bio­mark­ers and is sche­d­uled to read­out biop­sy da­ta in 1Q23. Two ad­di­tio­n­al SE­FAs (1024 and 6179) in Phase 1 clin­i­cal trials for pa­tients with dys­lipi­demia and the or­phan in­di­ca­tion IFALD, re­spec­tive­ly. [more in­for­ma­tion]
On­coRe­sponse is a pri­vate­ly held com­pany backed by in­vest­ment from MD An­der­son Can­cer Cen­ter, River­vest Ven­ture Part­n­ers, Qa­tar In­vest­ment Au­thor­i­ty, Red­mile Group, Mag­ne­tar Group, Yon­jin Ven­ture, Ber­ing Cap­i­tal, ARCH Ven­ture Part­n­ers, Helsinn In­vest­ment Fund, Ca­naan Part­n­ers, Great­Point Ven­tures, Take­da Ven­tures, Buchang Phar­ma (Chi­na), Alexan­dria Re­al Es­tate Equi­ties and Wil­li­am Marsh Rice Uni­ver­si­ty. For more in­for­ma­tion please vis­it www.on­core­spon­ and fol­low us on LinkedIn and Twit­ter. [more in­for­ma­tion]
Orum has a nov­el and pro­pri­e­tary next gen­er­a­tion tar­get­ed pro­tein degra­da­tion plat­form, AnDC (Anti­body neoDe­grad­er Con­ju­gate), that en­ables tu­mor spe­cif­ic tar­get­ing for mul­ti­ple in­di­ca­tions. Orum's two lead pipe­line prod­ucts, ORM-5029 in solid tu­mor and ORM-6151 in blood can­cer, are cur­rent­ly in the IND-en­abling stage and are ex­pect­ed to file IND in 2022 and 2023, re­spec­tive­ly. Strong R&D team with in­dus­try vet­er­ans in mAb/ADC dis­cov­ery and physics based mod­el­ing pro­vides Orum with an un­matched R&D en­gine to dis­cov­er and de­vel­op mul­ti­ple plat­forms with pipe­line prod­ucts with pre­ci­sion and speed. [more in­for­ma­tion]
Plex­i­um is the pre­mi­er, next-gen­er­a­tion Tar­get­ed Pro­tein Degra­da­tion (TPD) com­pany seek­ing to dis­cov­er a wide range of mono­va­lent tar­get pro­tein de­graders that ad­dress the lim­i­ta­tions of heter­ob­i­func­tio­n­al de­graders and cere­blon IMiDs. The com­pany is pow­ered by its pro­pri­e­tary drug dis­cov­ery plat­form de­signed to iden­ti­fy nov­el small molecules that in­duce se­lec­tive degra­da­tion of drug tar­get pro­teins through E3 li­g­ase me­di­at­ed pro­tea­so­mal degra­da­tion. From molec­u­lar glues to mono­va­lent de­graders, Plex­i­um is ad­vanc­ing a pipe­line of nov­el tar­get­ed pro­tein de­graders for the treat­ment of can­cer, neu­rode­gen­er­a­tion, and other dis­eas­es. [more in­for­ma­tion]
Prile­nia is a clin­i­cal stage biotech com­pany, led by Michael Hay­den, MD, PhD., to­gether with a high­ly ex­pe­ri­enced team with a track re­cord of suc­cess. Michael is a world-renowned sci­en­tist in Hunt­ing­ton Dis­ease re­search. He is the former Presi­dent of Glob­al R&D and Chief Sci­en­tif­ic Of­fi­cer at Te­va Phar­ma­ceu­ti­cals, where he led the de­vel­op­ment of ~35 new prod­ucts to­wards ap­pro­val in sev­er­al ma­jor mar­kets, pre­dom­i­nant­ly in CNS. The com­pany has re­cent­ly raised $68.5M in a Se­ries A fi­nanc­ing round to launch [more in­for­ma­tion]
A phar­ma­ceu­ti­cal drug dis­cov­ery com­pany with pro­line de­rived mo­d­ules (ProMs) as the world’s first PRM struc­ture mim­ick­ing build­ing blocks. The com­pany de­vel­ops a new class of drugs and is able to ad­dress yet un­drug­gable con­sid­ered tar­gets that are re­lat­ed to vari­ous in­di­ca­tions. For its first of many use-cas­es, PRO­SION has al­ready shown a re­mark­able in vi­vo ef­fect of its ProM-based an­ti-me­tastat­ic in­hibi­tor – both in pan­cre­at­ic and breast can­cer xeno­graft ro­dent mod­els. [more in­for­ma­tion]
Revitope Oncology
The lead­ing next gen­er­a­tion con­di­tio­n­al­ly ac­ti­vat­ed T cell en­gager com­pany lev­er­ag­ing its Two­GATE™ plat­form to ad­dress ar­eas of un­met need for safer and more ef­fec­tive can­cer im­munother­a­pies. Re­vi­tope’sT­wo­GATE™ drugs tar­get a pair of anti­gens co-ex­pressed on the sur­face of can­cer cells to achieve an un­par­al­leled de­gree of tu­mor se­lec­tiv­i­ty and avoid toxic­i­ty on healthy cells and tis­sues.” [more in­for­ma­tion]
Shoreline Biosciences
Shore­line Bio­s­ciences is de­vel­op­ing clin­i­cal­ly ef­fec­tive al­lo­gene­ic, off-the-shelf, tar­get­ed, and stan­dardized im­munother­a­pies us­ing in­tel­li­gent­ly en­gi­neered in­duced Pluripo­tent Stem Cell (iP­SC)-de­rived NK cells and macrophages for se­ri­ous dis­eas­es. Shore­line’s pro­pri­e­tary cell ther­a­py plat­form is based on deep ex­per­tise in iP­SC dif­fer­en­ti­a­tion meth­ods and ge­net­ic pro­gram­ming of the IL-15/CISH path­way for en­hanced per­sis­tence and tu­mor killing. In ad­di­tion, the com­pany aims to re­s­tore tis­sue home­os­ta­sis and func­tion by in­tro­duc­ing en­gi­neered macrophages for fi­brot­ic and in­flam­ma­to­ry patholo­gies. [more in­for­ma­tion]
ShouTi Inc.
Shou­Ti is a glob­al drug dis­cov­ery com­pany lev­er­ag­ing its break­through com­pu­ta­tio­n­al and struc­ture-based GPCR drug dis­cov­ery plat­form to re­place bi­o­log­ics and pep­tides with best-in-class small molecules. Their goal is to trans­form ex­pen­sive, less sta­ble, dif­fi­cult to tran­s­port or ad­min­is­ter ther­a­peu­tics in­to in­no­va­tive, ra­tio­n­al­ly de­signed, world class small molecule medicines that will be ac­ces­si­ble to pa­tients glob­al­ly. Shou­Ti’s vi­sion is to im­prove world health by bet­ter treat­ing chron­ic dis­eas­es such as car­dio­vas­cu­lar dis­ease and di­a­betes which are rapid­ly in­creas­ing and rep­re­sent over 60% of the glob­al dis­ease bur­den. [more in­for­ma­tion]
Solebury Strategic Communications
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. The firm’s glob­al reach ex­tends through a net­work of of­fices in New York, Bos­ton, San Fran­cis­co, Lon­don, Syd­ney and Shang­hai with con­tacts in all ma­jor fi­nan­cial cen­ters, help­ing clients to con­nect with the right in­ves­tors. [more in­for­ma­tion]
Th­ese nov­el medicines could form the ba­sis of a suite of new sight-sav­ing treat­ments with po­ten­tial ap­pli­ca­tions across many other reti­nal dis­eas­es, re­gard­less of ge­net­ic cause. The Com­pany is sup­port­ed by a strong, in­ter­na­tio­n­al­ly renowned team who aim to har­ness the po­ten­tial of ge­nom­ic medicine to de­liv­er new treat­ments to all oc­u­lar dis­ease pa­tients as quick­ly as pos­si­ble. Spar­ingVi­sion has raised &eu­ro;60 mil­lion to date and its in­ves­tors in­clude 4BIO Cap­i­tal, Ad­vent France Biotech­nol­o­gy, Bpifrance, Foun­da­tion Fight­ing Blind­ness (US), Fon­da­tion Voir & En­ten­dre, UPMC En­ter­pris­es, Jei­to Cap­i­tal and Ysios Cap­i­tal. [more in­for­ma­tion]
SphingoTec GmbH
Th­ese tests al­low for the di­ag­no­sis, out­come pre­dic­tion, and mon­i­tor­ing of acute med­i­cal con­di­tions, such as sep­tic shock, cir­cu­la­to­ry fail­ure, acute heart fail­ure and acute kid­ney in­jury. Sphin­goTec’s first-in-class tests are made avai­l­able on its pro­pri­e­tary whole-blood point-of-care Nexus IB10 plat­form for con­ve­nient and rapid test­ing in near-pa­tient and lab­o­ra­to­ry sett­ings along­side a broad port­fo­lio of stan­dard-of-care test for acute care. [more in­for­ma­tion]
Systems Oncology
Dde­vel­op­ing a new class of mul­ti­mo­dal RNA ther­a­peu­tics that si­mul­ta­ne­ous­ly si­lence the right com­bi­na­tion of dis­ease tar­gets with a sin­gle RNA molecule to im­prove out­comes and com­bat emerg­ing drug re­sis­tance. Our Ar­romerTM plat­form is used to dig­i­tal­ly en­gi­neer and rapid­ly pro­duce self-de­liv­er­ing ther­a­peu­tics which are di­rect­ed to spe­cif­ic tis­sues with un­prece­dent­ed pre­ci­sion and ac­cu­ra­cy. We are fo­cused on build­ing a pipe­line of drug prod­ucts in on­col­o­gy, yet our mul­ti­mo­dal RNA ther­a­peu­tics plat­form can be [more in­for­ma­tion]
Tarveda Therapeutics
is dis­cov­er­ing and de­vel­op­ing a new class of po­tent and se­lec­tive mi­nia­ture drug con­ju­gates (Pen­tarins®) for the treat­ment of pa­tients with a wide range of solid tu­mors. PEN-221 is a mi­nia­ture drug con­ju­gate in clin­i­cal eval­u­a­tion for the treat­ment of pa­tients with so­ma­to­s­tatin re­cep­tor 2 (SSTR2) ex­press­ing neu­roen­docrine, small cell lung and other solid tu­mors. PEN-221 is high­ly se­lec­tive for SSTR2 and is de­signed to rapid­ly pen­e­trate deep in­to solid tu­mors where it ac­cu­mu­lates and re­leas­es its po­tent DM1 pay­load over time within the tu­mor cells. [more in­for­ma­tion]
Totus Medicines
[more in­for­ma­tion]
Treos Bio
De­vel­ops pre­ci­sion pep­tide can­cer im­munother­a­pies us­ing pa­tient HLA tar­get recog­ni­tion ge­net­ics based on pro­pri­e­tary com­pu­ta­tio­n­al da­ta sci­ence. Tre­os’ lead can­di­date is Po­lyPEPI-1018, an off-the-shelf im­munother­a­py for the treat­ment of me­tastat­ic col­orec­tal can­cer cur­rent­ly in a bio­mark­er-based Phase 1b clin­i­cal trial. Tre­os has raised $42 mil­lion to date. [more in­for­ma­tion]
XyloCor Therapeutics
Xy­lo­Cor Ther­a­peu­tics is a bio-phar­ma­ceu­ti­cal com­pany de­vel­op­ing gene ther­a­py for peo­ple with ad­vanced coro­nary artery dis­ease. It's lead drug can­di­date, XC001, is cur­rent­ly in Phase 2 with re­sults re­port­ing out in 2022 and 2023. Promis­ing Phase 1 re­sults were pre­sent­ed ear­li­er this year. [more in­for­ma­tion]